German drugmaker Merck KGaA said on Monday it would acquire UK-based ​Silence Therapeutics in an all-cash deal for about $1.3 billion, bolstering ‌its pipeline of targeted medicines and adding RNA-targeting drug technology.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in